Imunon 3Q 2026: EPS ($0.64) — 10-Q Summary
Imunon (IMNN) reported a wider net loss of $3.81M in Q3 2026, though diluted EPS improved to ($0.64) from ($1.16) YoY. Operating expenses decreased 1%, with R&D costs down 6%. The OVATION 3 trial enrollment exceeded expectations, and the company advanced its NCI collaboration and MRD study. Imunon discontinued PLACCINE and IMNN-101 development in Q1 2026.
How this was made

The 30-second read
Why it matters
The disclosed wider net loss and EPS decline suggest short‑term downside, but reduced operating expenses and trial enrollment progress may offer longer‑term upside if milestones are met.
Market read
Micro‑cap biotech earnings with loss guidance typically trigger price pressure; investors will watch trial updates for catalyst potential.
What to watch
Potential future partnership or licensing deals not disclosed in the 10‑Q could mitigate loss concerns.
Background
Imunon is a pre‑revenue clinical‑stage biotech reporting its Q3 2026 results via a 10‑Q filing.
Ticker impact
Imunon filed its 10‑Q reporting a wider net loss and a 44.8% improvement in EPS to $‑0.64 versus last year.
likely pressure as the market prices in the widened loss and modest expense reductions
Micro‑cap biotech earnings often move sharply on loss guidance; the loss widening outweighs expense easing.
Market effects
Highlights ongoing challenges in early‑stage biotech cash burn and trial progress.
Limited to US biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech community.
Counterpoint
If the trial enrollment exceeds expectations, the stock could rally on upside potential.
Key entities
- companyImunon, Inc.
Pre‑revenue clinical‑stage biotechnology firm.

